Even though there is a significant overlap in the approved clinical indications for PD-1 antibodies versus PD-L1 antibodies, there are specific indications including Hodgkin lymphoma, head and neck cancer, and colorectal cancers in which only PD-1 antibodies are approved. This evidence concerns the gene PDCD1 and Hodgkins lymphoma.